Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c
February 22, 2022 7:14 AM ESTEsperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($1.77), $0.50 better than the analyst estimate of ($2.27). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.48 million.
2022 Financial Outlook:
Research and Development expenses for the full year 2022 are expected to be... More
